title: Increased APOBEC3B Predicts Worse Outcomes in Lung Cancer: A Comprehensive Retrospective Study.
abstract: Lung cancer ranks as the most common and lethal malignancy in America and worldwide. APOBEC3B is a newly identified DNA cytosine deaminase, which is supposed to function as a major source of DNA mutation in many different tumors. In this study, we combine the data of online databases and two hundred and twenty-one primary non-small-cell lung carcinoma (NSCLC) specimens from Sun Yat-sen University Cancer Center to investigate, for the first time, the clinical role of APOBEC3B in lung cancer. We found that the APOBEC3 expression was commonly elevated in NSCLC tissues and overexpression of APOBEC3B was correlated with unfavorable prognosis of the patients with NSCLC. Furthermore, APOBEC3B expression was associated with nodal status, TNM staging and adjuvant chemotherapy of the patients with NSCLC. Further research is warranted.
authors.affiliation: 1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, P.R. China;; 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, P.R. China;
authors.forename: Shumei
authors.initials: S
authors.lastname: Yan
authors.affiliation: 3. Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA;
authors.forename: Fan
authors.initials: F
authors.lastname: He
authors.affiliation: 4. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou City, Guangdong Province, P.R. China;
authors.forename: Bei
authors.initials: B
authors.lastname: Gao
authors.affiliation: 5. Department of Biological Sciences, University of Illinois at Chicago, Chicago, Illinois 60607, USA.
authors.forename: Huini
authors.initials: H
authors.lastname: Wu
authors.affiliation: 1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, P.R. China;; 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, P.R. China;
authors.forename: Mei
authors.initials: M
authors.lastname: Li
authors.affiliation: 1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, P.R. China;; 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, P.R. China;
authors.forename: Liyun
authors.initials: L
authors.lastname: Huang
authors.affiliation: 1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, P.R. China;; 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, P.R. China;
authors.forename: Jianzhong
authors.initials: J
authors.lastname: Liang
authors.affiliation: 1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, P.R. China;; 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, P.R. China;
authors.forename: Qiuliang
authors.initials: Q
authors.lastname: Wu
authors.affiliation: 1. State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou City, Guangdong Province, P.R. China;; 2. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, P.R. China;
authors.forename: Yong
authors.initials: Y
authors.lastname: Li
keywords: APOBEC3B; immunohistochemistry; non-small-cell lung cancer; prognosis.